Baxter Extraneal Phase IV Mortality Study Recommended By FDA Committee
Executive Summary
Baxter's dialysis agent Extraneal should be studied in Phase IV trials measuring hypertension and mortality, FDA's Cardiovascular & Renal Drugs Advisory Committee recommended Aug. 9.
You may also be interested in...
Baxter Extraneal Hypoglycemia Testing Program Is Condition Of FDA Approval
Baxter will initiate an Extraneal physician and patient educational campaign to help avoid falsely elevated glucose tests following FDA approval of the peritoneal dialysis solution
Baxter Extraneal Hypoglycemia Testing Program Is Condition Of FDA Approval
Baxter will initiate an Extraneal physician and patient educational campaign to help avoid falsely elevated glucose tests following FDA approval of the peritoneal dialysis solution
Pfizer Cardura Potential Labeling Changes Should Await More Data - Cmte.
Any potential changes to Pfizer's antihypertensive therapy Cardura (doxazosin) labeling should await additional data from NIH's ALLHAT study, FDA's Cardiovascular & Renal Drugs Advisory Committee said May 24.